Sensei Biotherapeutics (SNSE -4.75%) is a clinical-stage immunotherapy company developing innovative antibody treatments for cancer. On August 5, 2025, it reported financial results for the second quarter of 2025. The key news was that loss per share was $(3.91) in Q2 2025 (GAAP), which was significantly better than the$(5.60) loss analysts had expected. The company reported a net loss of $4.9 million in Q2 2025 (GAAP) compared to a$7.1 million GAAP net loss for Q2 2024. No revenue was reported, consisten ...